In vitro evaluation of ABT-719, a novel DNA gyrase inhibitor (Q35113781)

6 August 2017

In vitro evaluation of ABT-719, a novel DNA gyrase inhibitor (English)

1 reference

6 August 2017

Flamm RK

1

1 reference

6 August 2017

Vojtko C

2

1 reference

6 August 2017

Chu DT

3

1 reference

6 August 2017

Li Q

4

1 reference

6 August 2017

Beyer J

5

1 reference

6 August 2017

Hensey D

6

1 reference

6 August 2017

Ramer N

7

1 reference

6 August 2017

Clement JJ

8

1 reference

6 August 2017

Tanaka SK

9

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 April 1995

1 reference

Antimicrobial Agents and Chemotherapy

6 August 2017

1 reference

6 August 2017

39

1 reference

6 August 2017

964-970

1 reference

6 August 2017

4

1 reference

In vitro and in vivo evaluations of A-80556, a new fluoroquinolone

6 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162662

Quinolones in the treatment of lower respiratory tract infections

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162662

Comparative in vitro activities of several new fluoroquinolones and beta-lactam antimicrobial agents against community isolates of Streptococcus pneumoniae

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162662

In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162662

Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162662

Comparative activity of fluorinated quinolones in acute and subacute Streptococcus pneumoniae pneumonia models: efficacy of temafloxacin

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162662

The in-vitro activity of temafloxacin compared with other antimicrobial agents

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162662

Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States, I. Study on the threat of emerging resistances: real or perceived? Fluoroquinolone Resistance Surveillance Group.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162662

Multicenter in vitro comparative study of fluoroquinolones after four years of widespread clinical use

27 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/7786004

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Antistaphylococcal activity of the fluoroquinolones CI-960, PD 131628, sparfloxacin, ofloxacin and ciprofloxacin

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/7786004

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1128/AAC.39.4.964

1 reference

6 August 2017

1 reference

6 August 2017

1 reference